Tertiary hyperparathyroidism

Kurt A. Kennel, Bart Clarke

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Secondary hyperparathyroidism (SHP) occurs in multiple disorders, most commonly renal and gastrointestinal disease, to defend against hypocalcemia and hyperphosphatemia. If such disorders are left untreated or are undertreated, chronic stimulation of parathyroid tissue may lead to parathyroid hyperplasia. Medical therapy to correct hypocalcemia or hyperphosphatemia or to directly suppress parathyroid gland growth usually corrects SHP. Occasionally, sufficient parathyroid cell mass is achieved such that even basal (i.e., suppressed) PTH production is in excess of requirements to correct hypocalcemia. Monoclonal expansion of chief cells with reduced expression of vitamin D and calcium-sensing receptors may also contribute to parathyroid autonomy and hypercalcemia that may ensue. This state, referred to as tertiary hyperparathyroidism (THP), may require surgical treatment as hypercalcemia may limit options for medical therapy. Pseudohypoparathyroidism (PHP) is an uncommon disorder characterized by resistance to PTH action leading to hypocalcemia, hyperphosphatemia, secondary elevations in PTH and, rarely, THP. In PHP, the medical and surgical approaches to THP must be carefully planned, given that normalization of PTH concentrations may not be desirable.

Original languageEnglish (US)
Title of host publicationHyperparathyroidism
Subtitle of host publicationA Clinical Casebook
PublisherSpringer International Publishing
Pages179-188
Number of pages10
ISBN (Electronic)9783319258805
ISBN (Print)9783319258782
DOIs
StatePublished - Jan 1 2016

Fingerprint

Hypocalcemia
Hyperparathyroidism
Hyperphosphatemia
Pseudohypoparathyroidism
Secondary Hyperparathyroidism
Hypercalcemia
Calcium-Sensing Receptors
Parathyroid Glands
Gastrointestinal Diseases
Vitamin D
Hyperplasia
Kidney
Therapeutics
Growth

Keywords

  • Cinacalcet
  • Parathyroid hormone resistance
  • Parathyroid hyperplasia
  • Pseudohypoparathyroidism
  • Secondary hyperparathyroidism
  • Subtotal parathyroidectomy
  • Tertiary hyperparathyroidism

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kennel, K. A., & Clarke, B. (2016). Tertiary hyperparathyroidism. In Hyperparathyroidism: A Clinical Casebook (pp. 179-188). Springer International Publishing. https://doi.org/10.1007/978-3-319-25880-5_20

Tertiary hyperparathyroidism. / Kennel, Kurt A.; Clarke, Bart.

Hyperparathyroidism: A Clinical Casebook. Springer International Publishing, 2016. p. 179-188.

Research output: Chapter in Book/Report/Conference proceedingChapter

Kennel, KA & Clarke, B 2016, Tertiary hyperparathyroidism. in Hyperparathyroidism: A Clinical Casebook. Springer International Publishing, pp. 179-188. https://doi.org/10.1007/978-3-319-25880-5_20
Kennel KA, Clarke B. Tertiary hyperparathyroidism. In Hyperparathyroidism: A Clinical Casebook. Springer International Publishing. 2016. p. 179-188 https://doi.org/10.1007/978-3-319-25880-5_20
Kennel, Kurt A. ; Clarke, Bart. / Tertiary hyperparathyroidism. Hyperparathyroidism: A Clinical Casebook. Springer International Publishing, 2016. pp. 179-188
@inbook{15354bb1fbbe40f69ae8f10e7829cc6a,
title = "Tertiary hyperparathyroidism",
abstract = "Secondary hyperparathyroidism (SHP) occurs in multiple disorders, most commonly renal and gastrointestinal disease, to defend against hypocalcemia and hyperphosphatemia. If such disorders are left untreated or are undertreated, chronic stimulation of parathyroid tissue may lead to parathyroid hyperplasia. Medical therapy to correct hypocalcemia or hyperphosphatemia or to directly suppress parathyroid gland growth usually corrects SHP. Occasionally, sufficient parathyroid cell mass is achieved such that even basal (i.e., suppressed) PTH production is in excess of requirements to correct hypocalcemia. Monoclonal expansion of chief cells with reduced expression of vitamin D and calcium-sensing receptors may also contribute to parathyroid autonomy and hypercalcemia that may ensue. This state, referred to as tertiary hyperparathyroidism (THP), may require surgical treatment as hypercalcemia may limit options for medical therapy. Pseudohypoparathyroidism (PHP) is an uncommon disorder characterized by resistance to PTH action leading to hypocalcemia, hyperphosphatemia, secondary elevations in PTH and, rarely, THP. In PHP, the medical and surgical approaches to THP must be carefully planned, given that normalization of PTH concentrations may not be desirable.",
keywords = "Cinacalcet, Parathyroid hormone resistance, Parathyroid hyperplasia, Pseudohypoparathyroidism, Secondary hyperparathyroidism, Subtotal parathyroidectomy, Tertiary hyperparathyroidism",
author = "Kennel, {Kurt A.} and Bart Clarke",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-25880-5_20",
language = "English (US)",
isbn = "9783319258782",
pages = "179--188",
booktitle = "Hyperparathyroidism",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Tertiary hyperparathyroidism

AU - Kennel, Kurt A.

AU - Clarke, Bart

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Secondary hyperparathyroidism (SHP) occurs in multiple disorders, most commonly renal and gastrointestinal disease, to defend against hypocalcemia and hyperphosphatemia. If such disorders are left untreated or are undertreated, chronic stimulation of parathyroid tissue may lead to parathyroid hyperplasia. Medical therapy to correct hypocalcemia or hyperphosphatemia or to directly suppress parathyroid gland growth usually corrects SHP. Occasionally, sufficient parathyroid cell mass is achieved such that even basal (i.e., suppressed) PTH production is in excess of requirements to correct hypocalcemia. Monoclonal expansion of chief cells with reduced expression of vitamin D and calcium-sensing receptors may also contribute to parathyroid autonomy and hypercalcemia that may ensue. This state, referred to as tertiary hyperparathyroidism (THP), may require surgical treatment as hypercalcemia may limit options for medical therapy. Pseudohypoparathyroidism (PHP) is an uncommon disorder characterized by resistance to PTH action leading to hypocalcemia, hyperphosphatemia, secondary elevations in PTH and, rarely, THP. In PHP, the medical and surgical approaches to THP must be carefully planned, given that normalization of PTH concentrations may not be desirable.

AB - Secondary hyperparathyroidism (SHP) occurs in multiple disorders, most commonly renal and gastrointestinal disease, to defend against hypocalcemia and hyperphosphatemia. If such disorders are left untreated or are undertreated, chronic stimulation of parathyroid tissue may lead to parathyroid hyperplasia. Medical therapy to correct hypocalcemia or hyperphosphatemia or to directly suppress parathyroid gland growth usually corrects SHP. Occasionally, sufficient parathyroid cell mass is achieved such that even basal (i.e., suppressed) PTH production is in excess of requirements to correct hypocalcemia. Monoclonal expansion of chief cells with reduced expression of vitamin D and calcium-sensing receptors may also contribute to parathyroid autonomy and hypercalcemia that may ensue. This state, referred to as tertiary hyperparathyroidism (THP), may require surgical treatment as hypercalcemia may limit options for medical therapy. Pseudohypoparathyroidism (PHP) is an uncommon disorder characterized by resistance to PTH action leading to hypocalcemia, hyperphosphatemia, secondary elevations in PTH and, rarely, THP. In PHP, the medical and surgical approaches to THP must be carefully planned, given that normalization of PTH concentrations may not be desirable.

KW - Cinacalcet

KW - Parathyroid hormone resistance

KW - Parathyroid hyperplasia

KW - Pseudohypoparathyroidism

KW - Secondary hyperparathyroidism

KW - Subtotal parathyroidectomy

KW - Tertiary hyperparathyroidism

UR - http://www.scopus.com/inward/record.url?scp=84960348328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960348328&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-25880-5_20

DO - 10.1007/978-3-319-25880-5_20

M3 - Chapter

AN - SCOPUS:84960348328

SN - 9783319258782

SP - 179

EP - 188

BT - Hyperparathyroidism

PB - Springer International Publishing

ER -